British biopharmaceutical giant GSK sued Pfizer in Delaware federal court on Wednesday, accusing Pfizer’s respiratory syncytial virus (RSV) vaccine Abrysvo of violating GSK’s patent rights in its rival RSV shot Arexvy.
Tag Archive for: Arexvy
The Medicines and Healthcare products Regulatory Agency (MHRA) authorized GSK’s shot, called Arexvy, for active immunization to prevent lower respiratory tract disease caused by RSV in adults 60 years and older.
A panel of advisers to the U.S. Centers for Disease Control and Prevention (CDC) on Wednesday recommended that new vaccines from Pfizer and GSK to prevent severe respiratory syncytial virus (RSV) infections be available to older adults in the U.S. but stopped short of saying all of them should get the shots.
A panel of advisers to the U.S. Centers for Disease Control and Prevention (CDC) on Wednesday will vote on whether to recommend the use of recently approved vaccines from Pfizer and GSK to prevent severe respiratory syncytial virus (RSV) infections in older adults.
GSK on Wednesday said its vaccine for the respiratory syncytial virus (RSV), which recently won EU approval, showed strong long-term protection in older adults in a late-stage trial.
The approval on Wednesday by the European Commission, which follows a recent endorsement from the European Medicines Agency, comes about a month after the U.S. health regulator gave the drug Arexvy the green light.
The FDA has approved Pfizer’s respiratory syncytial virus vaccine, henceforth to carry the brand name Abrysvo, to prevent lower respiratory tract disease in older adults aged 60 years and above, the company announced Wednesday.